ライフサイエンスコーパス: pemphigoid

1 able medications in the treatment of bullous pemphigoid.

2 as found in patients with ocular cicatricial pemphigoid.

3 blood of some patients with mucous membrane pemphigoid.

4 skin of patients affected by mucous membrane pemphigoid.

5 rency in mid- to advanced ocular cicatricial pemphigoid.

6 een achieved in the field of mucous membrane pemphigoid.

7 s consistent with a diagnosis of cicatricial pemphigoid.

8 n are oral lichen planus and mucous membrane pemphigoid.

9 ouse model of the autoimmune disease bullous pemphigoid.

10 are involved in the pathogenesis of bullous pemphigoid.

11 opment of the autoimmune response in bullous pemphigoid.

12 3 IgG-induced mouse model of mucous membrane pemphigoid.

13 r surface disease such as ocular cicatricial pemphigoid.

14 rly lichen planus and benign mucous membrane pemphigoid.

15 istering disease that closely mimics bullous pemphigoid.

16 identified as an autoantigen in cicatricial pemphigoid.

17 ibodies (AAb) from patients with cicatricial pemphigoid.

18 ed with the blistering skin disease, bullous pemphigoid.

19 nt in the diagnosis and treatment of bullous pemphigoid.

20 phigoid/cicatricial pemphigoid, or anti-p200 pemphigoid.

21 id and help distinguishing them from bullous pemphigoid.

22 clinical clue to the diagnosis of anti-p200 pemphigoid.

23 on hands and feet, resembling dyshidrosiform pemphigoid.

24 cquisita or anti-laminin-332 mucous membrane pemphigoid.

25 he clinical benefit of patients with bullous pemphigoid.

26 ues to facilitate the diagnosis of anti-p200 pemphigoid.

27 the treatment of refractory mucous membrane pemphigoid.

28 inhibitor-associated noninflammatory bullous pemphigoid.

29 ers had immunopathologic findings of bullous pemphigoid.

30 n lesions can be the only symptom of bullous pemphigoid.

31 common disease presenting as DG, followed by pemphigoid.

32 al disease was diagnosed before the onset of pemphigoid.

33 e autoimmune skin blistering disease bullous pemphigoid.

34 ent testing in patients with mucous membrane pemphigoid.

35 ses were diagnosed as benign mucous membrane pemphigoid, 10 as lichen planus or lichenoid mucositis (

36 directed against the NC16A domain of bullous pemphigoid 180 (collagen XVII), a transmembrane protein

37 ind to this immunodominant region of bullous pemphigoid 180 are capable of inducing a skin disease th

38 ts, all of whom had circulating anti-bullous pemphigoid 180 autoantibodies, showed a specific prolife

39 ses were diagnosed as benign mucous membrane pemphigoid; 2 cases each of linear IgA disease and pemph

40 Twelve patients with anti-p200 pemphigoid (7 male and 5 female; mean age, 66.6 years) w

41 et of autoantibodies associated with bullous pemphigoid, a blistering skin disease.

42 ld also be resistant to experimental bullous pemphigoid, a disease with a pathogenesis thought to be

43 ad treatment-related serious adverse events (pemphigoid, adrenal insufficiency, liver disorder).

44 sive drugs used for treating mucous membrane pemphigoid and certain definitive categories of mucous m

45 d characterization of subsets of cicatricial pemphigoid and help distinguishing them from bullous pem

46 antibody-reactive site recognized by bullous pemphigoid and herpes gestationis sera) and the other in

47 ther autoimmune blistering diseases, bullous pemphigoid and herpes gestationis.

48 ients with other variants of mucous membrane pemphigoid and mAb GoH3 and BQ16 to integrin alpha6.

49 Differences between pemphigoid and normal conjunctival fibroblasts with resp

50 case of treatment-refractory mucous membrane pemphigoid and propose a mechanism to explain the lack o

51 ne for short-term blister control in bullous pemphigoid and significantly safer in the long-term.

52 desquamative gingivitis secondary to IgG/IgA pemphigoid and the management of this challenging varian

53 gus foliaceous, pemphigus, vulgaris, bullous pemphigoid, and benign chronic pemphigus, however, tPA i

54 aniridia, chemical/thermal burn, cicatrizing pemphigoid, and chronic ocular surface inflammation and

55 were diagnosed; there was 1 case of bullous pemphigoid; and 1 suspected case of paraneoplastic pemph

56 These mice represent a bullous pemphigoid animal model featuring pruritus in immunocomp

57 re reacted with sera from patients with oral pemphigoid, anti-alpha6 antibody, and control sera.

58 l transmembrane protein, the 180 kDa bullous pemphigoid antigen (BP180), also known as type XVII coll

59 ing primers specific for the 230 kDa bullous pemphigoid antigen (BPAG1), the 180 kDa bullous pemphigo

60 The 180-kDa bullous pemphigoid antigen (BPAG2) is a candidate gene/protein f

61 phigoid antigen (BPAG1), the 180 kDa bullous pemphigoid antigen (BPAG2), the alpha6 and beta4 chains

62 ivated the skin-specific promoter of bullous pemphigoid antigen 1 (BPAG-1).

63 Bullous pemphigoid antigen 1 (BPAG1) is a member of the plakin f

64 Bullous pemphigoid antigen 1 (BPAG1) is a member of the plakin f

65 ntain mutations in the gene encoding Bullous Pemphigoid Antigen 1 (BPAG1), or dystonin.

66 Bullous pemphigoid antigen 1 (BPAG1-e, also known as BP230) is a

67 identical to the neuronal isoform of bullous pemphigoid antigen 1 (BPAG1-n).

68 Other plakins, such as bullous pemphigoid antigen 1 and microtubule and actin cross-lin

69 Disruption of the BPAG1 (bullous pemphigoid antigen 1) gene results in progressive deteri

70 s, to which envoplakin, desmoplakin, bullous pemphigoid antigen 1, and plectin belong.

71 domain of the epithelial isoform of bullous pemphigoid antigen 1, BPAG1-e (also known as BP230).

72 esmoplakin and plectin, and, weakly, bullous pemphigoid antigen 1.

73 utoreactive T cells to an epitope of bullous pemphigoid antigen 180 kilodaltons were identified in th

74 integrin-associated plakin protein, bullous pemphigoid antigen 1e (BPAG1e) functions as a scaffold f

75 n or knockdown of the plakin protein Bullous Pemphigoid Antigen 1e (BPAG1e).

76 Bullous pemphigoid antigen 2 (BPAG2) is targeted by autoantibodi

77 in grafts from mice expressing human bullous pemphigoid antigen 2 (hBPAG2) in epidermal basement memb

78 .05), and in skin from patients with bullous pemphigoid antigen 2 mutations (n = 3) the counts were 5

79 such as the integrin alpha6beta4 and bullous pemphigoid antigen 2 within the hemidesmosomes along the

80 component of the shed ectodomain of bullous pemphigoid antigen 2.

81 d dynamics, and fails to recruit its bullous pemphigoid antigen binding partners.

82 The bullous pemphigoid antigen BPAG1 is required for keratin filamen

83 of zinc finger protein 185 (ZNF185), bullous pemphigoid antigen gene (BPAG1), and prostate secretory

84 est to the importance of the 180-kDa bullous pemphigoid antigen in the attachment of the epidermis to

85 A second bullous pemphigoid antigen of 180 kDa (BP180/BPAG2) is a type II

86 and include desmoplakin, the 230 kDa bullous pemphigoid antigen, and envoplakin.

87 interacting with Nck (SPIN90/WISH), bullous pemphigoid antigen-1, and calcium channel beta2.

88 proteins: one enriched with the two bullous pemphigoid antigens (BP230, BP180) and one enriched with

89 (cell adhesion molecules in desmosomes), and pemphigoid antigens are found in hemidesmosomes (which m

90 6beta4 integrin, plectin, and BPAGs (bullous pemphigoid antigens).

91 Pemphigus and bullous pemphigoid are autoantibody-mediated blistering skin dis

92 Pemphigus and bullous pemphigoid are distinct autoimmune blistering diseases t

93 confirmed the clinical diagnosis of IgG/IgA pemphigoid as the cause of desquamative gingivitis and t

94 + cells-issues of relevance to patients with pemphigoid as well as individuals undergoing gene replac

95 ontains all four of the well-defined bullous pemphigoid-associated antigenic sites.

96 ntly demonstrated that reactivity of bullous pemphigoid autoantibodies to the BP180 ectodomain is alm

97 techniques for detecting circulating bullous pemphigoid autoantibodies, including other enzyme-linked

98 0 and 230 kDa proteins recognized by bullous pemphigoid autoantibodies, LABD97 has been thought to re

99 hemidesmosome plaque is the 230-kDa bullous pemphigoid autoantigen (BP230/BPAG1), which connects dir

100 Cicatricial pemphigoid (benign mucous membrane pemphigoid) is an aut

101 this area: inflammatory process - cicatrical pemphigoid, benign neoplastic process - chondroma, malig

102 riodontal disease and benign mucous membrane pemphigoid (BMMP).

103 lit indirect immunofluorescence, and bullous pemphigoid (BP) 230 and BP180-NC16A ELISAs.

104 ed Hospitals with a new diagnosis of bullous pemphigoid (BP) between May 1, 1997 and September 1, 200

105 Bullous pemphigoid (BP) has been previously described to develop

106 Although predisposing factors for bullous pemphigoid (BP) have been recently established, no clini

107 Bullous pemphigoid (BP) is a bullous dermatosis associated with

108 Bullous pemphigoid (BP) is a subepidermal blistering disease ass

109 Bullous pemphigoid (BP) is a subepidermal blistering disease cha

110 Bullous pemphigoid (BP) is a subepidermal blistering disease cha

111 Bullous pemphigoid (BP) is an autoimmune bullous disease of the

112 Bullous pemphigoid (BP) is an autoimmune disease associated with

113 Bullous pemphigoid (BP) is an autoimmune disease characterized b

114 Bullous pemphigoid (BP) is an autoimmune skin disease characteri

115 Bullous pemphigoid (BP) is an autoimmune skin disease characteri

116 Bullous pemphigoid (BP) is an autoimmune skin disease characteri

117 Bullous pemphigoid (BP) is an autoimmune skin-blistering disease

118 Bullous pemphigoid (BP) is an autoimmune subepidermal blistering

119 Bullous pemphigoid (BP) is an autoimmune subepidermal blistering

120 Bullous pemphigoid (BP) is an autoimmune subepidermal blistering

121 Bullous pemphigoid (BP) is an inflammatory subepidermal blisteri

122 Bullous pemphigoid (BP) is an inflammatory subepidermal blisteri

123 Bullous pemphigoid (BP) is by far the most frequent autoimmune b

124 Bullous pemphigoid (BP) is characterized by the deposition of Ig

125 from the sera of some patients with bullous pemphigoid (BP) react with a 180 kDa protein termed BPAg

126 Bullous pemphigoid (BP), a common autoimmune blistering disease,

127 s long been a histologic hallmark of bullous pemphigoid (BP), a subepidermal autoimmune blistering di

128 paration in an experimental model of bullous pemphigoid (BP), an autoimmune disease.

129 d by autoantibodies in patients with bullous pemphigoid (BP), and absent in patients with one type of

130 om patients with pemphigus vulgaris, bullous pemphigoid (BP), and chronic atopic and chronic ocular r

131 ith a blistering skin disease called bullous pemphigoid (BP), is a transmembrane component of the hem

132 ents with MMP, 1 of 50 patients with bullous pemphigoid (BP), none of 7 with pemphigus, and 3 of 32 o

133 gG passive transfer murine models of bullous pemphigoid (BP), pemphigus foliaceus (PF), and pemphigus

134 The outcome of bullous pemphigoid (BP), the most frequent autoimmune skin-blist

135 cal disorders may be associated with bullous pemphigoid (BP).

136 d sequence of the 180 kDa antigen in bullous pemphigoid (BPAg2).

137 ding an experimental murine model of bullous pemphigoid by showing that the plasminogen/plasmin signa

138 pion repair in patients with mucous membrane pemphigoid can be achieved if control of inflammation is

139 quamative gingivitis associated with IgG/IgA pemphigoid can be challenging to diagnose and treat.

140 ermolysis bullosa acquisita, mucous membrane pemphigoid/cicatricial pemphigoid, or anti-p200 pemphigo

141 st year of life, with uncontrollable bullous pemphigoid, colitis, and proteinuria.

142 Together, these findings indicate that pemphigoid conjunctival fibroblasts have a profibrotic p

143 e compared the functional characteristics of pemphigoid conjunctival fibroblasts to normal conjunctiv

144 from a patient with severe oral cicatricial pemphigoid contained IgG anti-BMZ AAb.

145 ain definitive categories of mucous membrane pemphigoid continue to evolve.

146 Mucous membrane pemphigoid continues to be a potentially life and sight

147 Cicatricial pemphigoid (CP) is an autoimmune blistering disease that

148 derwent clinical evaluation with the Bullous Pemphigoid Disease Activity Index (BPDAI); and 36 patien

149 s experimental mouse models of pemphigus and pemphigoid disease are increasingly being used to unders

150 ized by sera from 20 untreated patients with pemphigoid disease limited to the oral cavity, and to de

151 mal (pemphigus) and subepidermal blistering (pemphigoid diseases and dermatitis herpetiformis).

152 Pemphigoid diseases are a group of well defined autoimmu

153 In eight pemphigoid diseases the target antigens have been identi

154 esterase 4, and leukotriene B4 inhibitors in pemphigoid disorders, and chimeric antigen receptor T ce

155 sis of pemphigus vulgaris/foliaceus, bullous pemphigoid, epidermolysis bullosa acquisita, mucous memb

156 om the MCW-1 domain, the predominant bullous pemphigoid epitope.

157 No differences between pemphigoid fibroblasts obtained from acutely inflamed ve

158 We found that pemphigoid fibroblasts showed increased cell division (P

159 utoantibodies, whereas the autoantibodies in pemphigoid fix complement and mediate inflammation.

160 ropose the unifying term pruritic nonbullous pemphigoid for all patients with immunopathologic findin

161 e propose the name "anti-laminin cicatricial pemphigoid" for this subset.

162 of grade 3 fatigue, one case each of grade 3 pemphigoid, grade 3 hypothyroidism, and grade 3 peripher

163 rmis to epidermal basement membrane (eg, the pemphigoid group of disorders [bullous, gestational, and

164 re-noncicatrizing disease>ocular cicatricial pemphigoid>chemical burns>Stevens-Johnson syndrome.

165 A unique antigen in oral mucous membrane pemphigoid has not yet been identified.

166 In the literature, patients with bullous pemphigoid have been reported to have itch without blist

167 Patients with one form of cicatricial pemphigoid have IgG antibasement membrane autoantibodies

168 such as Stevens-Johnson syndrome, and ocular pemphigoid have little hope of visual recovery from conv

169 here are now three bullous diseases, bullous pemphigoid, herpes gestationis, and cicatricial pemphigo

170 her patients with anti-laminin-5 cicatricial pemphigoid immunoprecipitated both laminin-6 and laminin

171 in 41.7% (20 of 48 eyes) and mucous membrane pemphigoid in 41.7% (20 of 48 eyes).

172 biopsy findings in 80% of the cases and with pemphigoid in 60%.

173 port describes the management of cicatricial pemphigoid in a patient with multiple sites of gingival

174 English literature have reported cicatricial pemphigoid in children, primarily as oral mucosal lesion

175 oth the oral and genital elements of IgG/IgA pemphigoid in this patient.

176 in the three different clinical variants of pemphigoid, involves the recognition by T cells of a cla

177 Bullous pemphigoid is a blistering skin disease characterized by

178 Bullous pemphigoid is a blistering skin disorder with increased

179 Mucous membrane pemphigoid or cicatricial pemphigoid is a mucocutaneous blistering disease charact

180 Anti-p200 pemphigoid is a rare subepidermal autoimmune blistering

181 Mucous membrane pemphigoid is an autoantibody-mediated disease predomina

182 Cicatricial pemphigoid is an autoimmune ulcerative condition that is

183 Ocular mucous membrane pemphigoid is an immunobullous disease in which excessiv

184 mong patients with oral only mucous membrane pemphigoid is estimated at 15-20% at 5 years.

185 Cicatricial pemphigoid is one of a number of mucocutaneous disorders

186 Anti-p200 pemphigoid is probably often misdiagnosed because of low

187 catricial pemphigoid (benign mucous membrane pemphigoid) is an autoimmune vesiculobullous disease tha

188 ts with immunopathologic findings of bullous pemphigoid, itch, and no blisters.

189 to evaluate the possible impact of gingival pemphigoid lesions on the human periodontium.

190 isted of pemphigus vulgaris, mucous membrane pemphigoid, lichen planus, linear immunoglobulin A disea

191 phigoid, pemphigus vulgaris, and cicatricial pemphigoid-like diseases did not recognize the 205-kDa p

192 In the inflammatory (bullous pemphigoid-like) EBA variant, autoantibody binding is fo

193 ch as the use of topical corticosteroids for pemphigoid may have played a pivotal role in improving t

194 The Pathogenesis of Pemphigus and Pemphigoid Meeting, organized by the Departments of Derm

195 immunobullous disease ocular mucous membrane pemphigoid (MMP) causes blindness; the pathogenesis of s

196 Mucous membrane pemphigoid (MMP) describes an autoimmune disease with a

197 t International Consensus on Mucous Membrane Pemphigoid (MMP) guidance, which recommends that clinica

198 Mucous membrane pemphigoid (MMP) has several subsets based on target ant

199 Mucous membrane pemphigoid (MMP) is a heterogeneous group of autoimmune

200 Mucous membrane pemphigoid (MMP) is a heterogeneous group of blistering

201 A rare variant of mucous membrane pemphigoid (MMP) is characterized by circulating anti-la

202 diagnosis and management of mucous membrane pemphigoid (MMP) published in the English literature sin

203 A case of anti-laminin-332 mucous membrane pemphigoid (MMP) that developed shortly after a diphther

204 th clinically typical ocular mucous membrane pemphigoid (MMP).

205 OCP), also labeled as ocular mucous membrane pemphigoid (MMP).

206 icacy of HDIG treatment in the pemphigus and pemphigoid models is dependent on FcRn.

207 lupus erythematosus (BSLE) (n = 3), bullous pemphigoid (n = 16), pemphigus (n = 11), and normal cont

208 igus vulgaris (n=40, USA and Japan), bullous pemphigoid (n=40, USA), and healthy donors (n=55, USA) s

209 Ocular cicatricial pemphigoid (OCP) is an autoimmune disease in which affec

210 Ocular cicatricial pemphigoid (OCP) is an autoimmune disease that affects m

211 MMP and ocular cicatricial pemphigoid (OCP) sera recognize beta4 integrin subunit,

212 cimens from patients with ocular cicatricial pemphigoid (OCP) were used.

213 junctiva of patients with ocular cicatricial pemphigoid (OCP), also labeled as ocular mucous membrane

214 patients with BP, 17 with ocular cicatricial pemphigoid (OCP), and 22 with oral pemphigoid (OP) to a

215 re in the pathogenesis of ocular cicatricial pemphigoid (OCP).

216 ant histologic feature in ocular cicatricial pemphigoid (OCP).

217 al histologic features in ocular cicatricial pemphigoid (OCP).

218 re in the pathogenesis of ocular cicatricial pemphigoid (OCP).

219 tibodies of patients with ocular cicatricial pemphigoid (OCP).

220 Ocular mucous membrane pemphigoid (OMMP) is an autoimmune disease involving the

221 Oral pemphigoid (OP) is a rare chronic autoimmune disease cha

222 the sera of patients with MMP, OCP, and oral pemphigoid (OP) recognize only their target antigens, an

223 catricial pemphigoid (OCP), and 22 with oral pemphigoid (OP) to a panel of 218 haplotypes of normal i

224 Mucous membrane pemphigoid or cicatricial pemphigoid is a mucocutaneous

225 says and expertise and classified as bullous pemphigoid or epidermolysis bullosa acquisita.

226 tural proteins that promote cell matrix (eg, pemphigoid) or cell-to-cell (eg, pemphigus) adhesion in

227 sita, mucous membrane pemphigoid/cicatricial pemphigoid, or anti-p200 pemphigoid.

228 but no oral disease (pure ocular cicatricial pemphigoid, p < 0.025).

229 d malposition resulting from mucous membrane pemphigoid, particularly cicatricial entropion, that req

230 upus erythematosus patients (n = 3), bullous pemphigoid patients (n = 15), and normal humans (n = 12)

231 About 25% of mucous membrane pemphigoid patients generate autoantibodies against the

232 Sera of oral pemphigoid patients selectively and specifically bound t

233 T cells from eight of 12 bullous pemphigoid patients, all of whom had circulating anti-bu

234 ed the autoimmune T cell response in bullous pemphigoid patients.

235 fied by the AAb from a subset of cicatricial pemphigoid patients.

236 ecific autoantibodies in the sera of bullous pemphigoid patients.

237 Sera from patients with bullous pemphigoid, pemphigus vulgaris, and cicatricial pemphigo

238 cle is to review articles on mucous membrane pemphigoid published in the English literature from 2006

239 To review articles on mucous membrane pemphigoid, published between June 2004-May 2005.

240 However, not all cases of mucous membrane pemphigoid respond to rituximab.

241 Oral pemphigoid sera and anti-alpha6 antibody produced separa

242 predominant epitope identified with bullous pemphigoid sera is located in the noncollagenous region

243 sera recognize beta4 integrin subunit, oral pemphigoid sera recognize alpha6 integrin subunit, and a

244 grin subunit, and anti-epiligrin cicatricial pemphigoid sera recognize laminin 5.

245 Of 50 randomly selected bullous pemphigoid sera tested, 47 (94%) were positive in this a

246 Interestingly, all three of the bullous pemphigoid sera that were negative in this assay had bee

247 g a skin disease that closely mimics bullous pemphigoid, supporting the hypothesis that epitopes with

248 per presents a case of childhood cicatricial pemphigoid that clinically manifested as necrotizing ulc

249 phigoid, herpes gestationis, and cicatricial pemphigoid, that are known to be associated with an auto

250 us membranes lose cell-cell adhesion, and in pemphigoid, the basal keratinocytes lose adhesion to the

251 ay be indistinguishable from that of bullous pemphigoid, the latter being the most common autoimmune

252 ised controlled trial of adults with bullous pemphigoid (three or more blisters at two or more sites

253 elderly patients, including scabies, bullous pemphigoid, transient acantholytic dermatosis, and mycos

254 Treatment for mucous membrane pemphigoid typically involves immunosuppressive drugs, i

255 ocular disorders, including ocular cicatrial pemphigoid, vernal keratoconjunctivitis, and pterygium.

256 ng IgA against an antigen in mucous membrane pemphigoid was found in about 20% of patients, without p

257 oglobulin as treatment of ocular cicatricial pemphigoid was found to be superior to conventional immu

258 ed phenotype exist in ocular mucous membrane pemphigoid, we compared the functional characteristics o

259 nger onset (<60 years) of ocular cicatricial pemphigoid were found to have disease evolution similar

260 r preliminary studies in humans with bullous pemphigoid, which is also associated with excessive leve

261 The most common of these diseases is bullous pemphigoid, which mainly affects older people and the re

262 to confirm the diagnosis of mucous membrane pemphigoid with consistency.

263 the pathogenicity of autoantibodies in oral pemphigoid, with an organ culture model.